In short, our results may imply that the observed anti-HCC effect of Ad-ΔB/TRAIL plus Ad-ΔB/IL-12 combination therapy was, partly, mediated by activating caspase cascade apoptotic pathway in HCC cells and tumour tissues. Here, TNFSF10 is linked to neoplasm.